Prevalence and associated factors of undiagnosed atrial fibrillation among end-stage renal disease patients on maintenance haemodialysis: a cross-sectional study

Izzat AlAwwa1*, Reham Al-Hindi2, Nadeen Alfraihat2, Ahmad Obeid2, Sarah Ibrahim2, Shatha Jallad3, Ahmad Al-Awwa4 and Akram Saleh1

Abstract

Background: Atrial fibrillation (AF) is the most prevalent sustained arrhythmia worldwide and it aggravates cardiovascular morbidity and mortality; however, this is largely under-diagnosed. Moreover, among end-stage renal disease patients on haemodialysis, AF is substantially more common and serious. The researchers conducted this study to assess the prevalence of, and the factors correlated with AF in Jordanian haemodialysis patients.

Methods: In a cross-sectional analysis conducted from October 2018 to February 2019 in four tertiary hospitals, the researchers enrolled all consenting patients aged 18 years or older who were on haemodialysis for at least three months prior to the study. We screened for AF clinically by pulse palpation, precordial auscultation, by an automated blood pressure monitor and an electrocardiogram. The researchers reported qualitative variables as counts and frequencies, while continuous variables were summarised using the mean or median where necessary. We used multiple logistic regression with backward selection to identify independent risk factors of AF.

Results: A total of 231 patients were enrolled; mean age was 54.8 ± 15.6 years (from 20 to 86), and 44.3% of them were women. The prevalence of AF was found to be 7.8% (95% CI, 4.8–12.2), with no gender disparity. Age (adjusted odds ratio [AOR] = 1.05; 95% CI, 1.01–1.10; *p* = 0.031), history of ischaemic heart disease (AOR = 3.74; 95% CI, 1.09–12.34; *p* = 0.033), history of smoking (AOR = 0.15; 95% CI, 0.02–0.60; *p* = 0.019), and low interdialytic weight gain (AOR = 0.50; 95% CI, 0.25–0.91; *p* = 0.031) were independently correlated to AF.

(Continued on next page)
Introduction

Atrial fibrillation (AF) is the commonest cardiac arrhythmia, and a global public health problem associated with high rates of hospitalisation, disability, and complications such as heart failure, cardiomyopathy, and cardio-embolic events like stroke [1–4]. The incidence and prevalence of AF have been on a rise globally especially in high-income European countries [1, 5]. In fact, about 33.5 million persons or 0.5% of the world’s population is estimated to have AF with age-adjusted prevalence rates of 596.2 and 373.1 per 100,000 in males and females, respectively. These prevalence rates in both genders were higher than previous values of 569.5 and 359.9 per 100,000 population reported in 1990 for men and women, respectively [5]. A similar increase in disability and mortality due to AF was also noted [5]. This rising prevalence of AF is in sync with the increasing cardiometabolic risk factors such as obesity, hypertension, diabetes, and an increasing population of elders globally [1].

It is estimated that between 11 and 13% of the world’s population is affected by chronic kidney disease (CKD); with the prevalence of stage 5 CKD estimated at about 0.1% [6]. Worsening kidney function has been associated with the risk of cardiovascular complications especially among patients on haemodialysis [7–9]. Cardiovascular complications significantly contribute up to 50% of all-cause mortality among patients with end stage renal disease (ESRD) on haemodialysis in the United States [10], with sudden cardiac death, arrhythmia, heart failure, and coronary artery disease reported as the main cardiovascular causes of mortality [8]. During haemodialysis, rapid fluctuations in haemodynamics and electrolyte concentrations, as well as the induction of hypoxemia increases the likelihood of developing arrhythmias [11]. Also, the incidence of AF increases after dialysis due to increase in cardiac dimensions [12–14]. Although arrhythmias developed during haemodialysis are mostly brief, asymptomatic, and self-limiting, they have been independently associated with higher mortality and cardiovascular events [15, 16]. The incidence of AF in patients with ESRD on dialysis varies between 6.6 to 20% and is 2 to 3 times higher than in the general population [17–20]. Furthermore, AF in patients with ESRD is associated with higher morbidity and up to 50% mortality rate in a cohort of patients with ESRD undergoing haemodialysis [19, 21, 22]. Despite the significant impact of AF in patients with ESRD, this remains a neglected topic in the scientific literature, especially in the Middle East in general and Jordan in particular, as a detailed PubMed search revealed no study on the prevalence, incidence, or mortality of AF in patients with ESRD in the region.

This study sought to evaluate the prevalence and factors associated with previously undiagnosed AF among patients with ESRD on maintenance haemodialysis. The information from the study is vital to enlighten practice in the Middle East and add to the limited literature on the topic globally.

Methods

Study design and setting

This was a cross-sectional analysis conducted from October 2018 to February 2019, in four haemodialysis centres in Amman. Each dialysis unit serves about 50 to 150 patients and is managed by a nephrologist.

Study population and sample size

All patients with ESRD undergoing haemodialysis were screened for eligibility and then invited to take part in the study. The researchers enrolled all consenting participants aged 18 years or older, diagnosed with ESRD and had received haemodialysis for at least three months prior to the study. We excluded patients with a previous diagnosis of arrhythmia or AF, and any psychiatric, psychological, or debilitating disorder which could prevent the patients from either being interviewed or understanding the questions.

Using the Cochrane’s formula below, we calculated a minimum acceptable sample size (n) of 167 participants.

\[ n = \frac{Z^2 \times P(1-P)}{d^2} \]

where:

- \( Z \) = Z statistics = 1.96 for a 95% confidence interval (CI);
- \( P \) = prevalence of subclinical AF among patients with
- \( d \) = minimum acceptable sample size (n) of 167 participants.

Conclusions: The prevalence of AF among patients on maintenance haemodialysis is high, but largely undiagnosed. AF is generally associated with advancing age, history of ischaemic heart disease, lower interdialytic weight gain, and history of smoking. We suggest routine check-up of AF in this high-risk group of patients as anticoagulant therapy if indicated may prevent serious complications. However, there is a need for large-scale cohort studies and for the creation of regional chronic kidney disease and dialysis registries in the Middle East region.

Keywords: Atrial fibrillation, Nonvalvular, Arrhythmia, End stage renal disease, Haemodialysis, Stroke, Cardiovascular risk, Subclinical, Anticoagulation
ESRD on dialysis = 0.124 [18]; and \( d = \) margin of error which was considered to be 5% for this study.

Participants were consecutively enrolled in the study.

**Ethical consideration**

The study protocol was approved by the ethical review boards (IRB) of the participating hospitals. All patients signed an informed written consent form after being explained the details of the research, its procedure, the potential benefits and harm, and their questions were satisfactorily answered.

**Study procedure and data collection**

Patients were interviewed by trained final year medical students using a pre-designed questionnaire to collect information on the general demographic information (e.g. age, gender, marital status, and occupation), past medical history (e.g. Family history of hypertension, history of diabetes mellitus, and ischaemic heart disease), and dialysis related information (e.g. duration of dialysis, dialysis access and number of sessions per week). Information on the patient’s drugs and results of the laboratory tests were also collected from the patient’s medical file. The patient’s body mass index was computed using the patient’s weight (measured in the nearest 10 g) and height (in centimetres). An automated blood pressure (BP) monitor with irregular heartbeat detector (Omron M6, Omron Healthcare Co. Ltd., Japan) was used to detect the presence of irregular heartbeat during BP recording. This device has been clinically validated for detecting AF during blood pressure recording with a sensitivity of 98.7% [18].

At baseline, prior to haemodialysis, we screened all patients for AF by palpating their pulse and auscultating their heart to check for irregularities using the automated BP monitor and a 12-lead electrocardiogram (ECG). The patients’ BP and pulse were also monitored during dialysis using the automated BP monitor. An irregular heartbeat sign on the device screen would flash if an irregular heartbeat was detected. If the sign flashed, the BP was remeasured after five minutes to confirm the presence of the sign. A second ECG was obtained if the sign persisted. Only patients with an episode of AF on the ECG findings were interpreted blindly by a consultant cardiologist in two separate sessions.

**Statistical analysis**

We used Microsoft Excel 2010 spreadsheets for data entry and curation, and the statistical software R (version 3.5.3, The R Foundation for statistical computing, Vienna, Austria) for data analysis. We reported qualitative variables as counts and proportions while we summarized quantitative variables as means and medians with their corresponding standard deviation (SD) and interquartile range (IQR), respectively. Histograms and probability distribution plots were used to visually assess continuous variables for normality and presence of outliers. The Fisher’s exact test was used to compare categorical variables, while the student t-test or Mann-Whitney U test was used to compare continuous and categorical variables as appropriate. We determined independent factors correlated with AF using multiple logistic regression analysis utilizing backward elimination method [23]. Only variables with \( p \)-values less than 0.1 on bivariate analysis, with the exception of gender, were evaluated using backward elimination method and based on the Akaike information criterion (AIC) for final inclusion in the multiple regression model [23]. Lower AIC signified a better model. The best model (based on the AIC) constituted of the variables: age, history of smoking, average weight gain during dialysis, history of ischaemic heart disease, and diastolic blood pressure before dialysis. Two-tailed \( p \)-values below 0.05 were considered statistically significant.

**Results**

**Description of the study population**

Collectively, we enrolled 231 participants in this study. Only one candidate was excluded because of previous diagnosis of AF. The mean age of the participants was 54.8 years (SD = 15.6) and participants who developed atrial fibrillation were significantly older than their counterparts without atrial fibrillation \((p < 0.001)\), Table 1. About 44.2% of the participants were females and 71.7% were married. About 85% were Jordanians.

Three-quarters of the participants were hypertensive, almost 40 and 30% had diabetes mellitus or dyslipidemia, 14% had ischaemic heart disease while the presence of vulvulopathies were rare, Table 2.

On average, the participants had three sessions of dialysis per week, with each session lasting four hours. Over three-quarters of the route of access for dialysis was an arteriovenous fistula. Participants gained an average of 3.1 kg in between the dialysis sessions, Table 3.

About 90, 70, and 40% of the participants were on calcium, alpha 1 hydroxylase vitamin D, and beta-blockers. About 23% were on furosemide, Table 4.

**Prevalence of atrial fibrillation in the study population**

Eighteen out of the 231 participants were diagnosed with atrial fibrillation giving a prevalence of 7.8% (95% CI, 4.8–12.2) with no gender disparity \((p = 0.453)\), Table 1.

**Factors associated with atrial fibrillation**

The final multiple regression model predicted age (adjusted odds ratio [AOR] = 1.05, 95% CI, 1.01–1.10, \( p = 0.031)\), ischaemic heart disease (AOR = 3.74, 95% CI,
1.09–12.34, \( p = 0.033 \), history of smoking (AOR = 0.15, 95% CI, 0.02–0.60, \( p = 0.019 \)), and low interdialytic weight gain (AOR = 0.50, 95% CI, 0.25–0.91, \( p = 0.031 \)) as independent factors associated with the occurrence of atrial fibrillation with a very good accuracy (C statistics = 82.2%), Table 5. As shown by the Nagelkerke pseudoR2 value, 25.4% of the variation in the outcome variable was explained by the aforementioned independent variables.

The model was also a good fit for our data as was revealed by a non-significant Hosmer-Lemeshow test (Chi-square = 3.31, \( p = 0.913 \)), Table 5. Figures 1 and 2 display a good fit between the predicted data for both cases of atrial fibrillation and non-atrial fibrillation cases.

**Discussion**

We sought to evaluate the prevalence and factors associated with atrial fibrillation among ESRD on maintenance chronic haemodialysis. The high prevalence of 7.8% was linked to increasing age, history of smoking, history of ischaemic heart disease and lower interdialytic weight gain with a very good accuracy.

Very few studies have evaluated the prevalence of subclinical AF among ERSD patients on maintenance haemodialysis. The prevalence of AF in this study is similar to rates of 7.7 and 8.0% reported by Konisbrugge et al., 2017 [17] and Winkelmayer et al., 2011 [20] though much lower than those reported by Vazquez et al., in 2009 [18]. The lower prevalence in our study compared to that of Vazquez and colleagues is most likely due to the younger age of participants in our study as Vazquez et al. only recruited elderly participants (65 years or older). In addition, this could also be due to methodological differences as these studies were based on medical records contrary to our study as previously known cases of AF were excluded and we also depended on direct patient contact and an electrocardiogram to

**Table 1** Sociodemographic data of the study population

| Variables                  | Total N = 231 (100.0%) | AF N = 18 (7.8%) | No AF N = 213 (92.2%) | \( p \)-value |
|----------------------------|------------------------|-----------------|-----------------------|--------------|
| Mean age in years (±SD)    | 54.8 ± 15.6            | 65.9 ± 15.6     | 53.9 ± 10.5           | <0.001*      |
| Gender                     |                        |                 |                       | 0.453        |
| Females                   | 102 (44.2)             | 10 (55.6)       | 92 (43.2)             |              |
| Males                      | 129 (55.8)             | 8 (44.4)        | 121 (56.8)            |              |
| Marital Status             |                        |                 |                       | 0.092        |
| Married                    | 165 (71.7)             | 16 (88.9)       | 149 (70.0)            |              |
| Single                     | 65 (28)                | 2 (11.1)        | 64 (30.0)             |              |
| Nationality                |                        |                 |                       | 0.674        |
| Jordanian                  | 200 (86.6)             | 15 (83.3)       | 185 (86.9)            |              |
| Others                     | 31 (13.4)              | 3 (16.7)        | 28 (13.1)             |              |
| Body mass index (kg/m²) * (±SD) | 26.0 ± 5.6            | 26.2 ± 5.6      | 26.0 ± 5.6            | 0.914        |

*Mean ± SD; AF = atrial fibrillation; SD = standard deviation

**Table 2** Past Medical History of the participants

| Variables                           | Total N = 231 (100.0%) | AF N = 18 (7.8%) | No AF N = 213 (92.2%) | \( p \)-value |
|-------------------------------------|------------------------|-----------------|-----------------------|--------------|
| Hypertension, Yes (%)                | 174 (75.3)             | 15 (83.3)       | 159 (74.6)            | 0.412        |
| Diabetes mellitus, Yes (%)           | 91 (39.4)              | 10 (55.6)       | 81 (38.0)             | 0.143        |
| Dyslipidaemia, Yes (%)               | 68 (29.9)              | 6 (33.3)        | 62 (29.6)             | 0.738        |
| Ischemic heart disease, Yes (%)      | 33 (14.3)              | 6 (33.3)        | 27 (12.7)             | 0.016*       |
| Heart failure, Yes (%)               | 34 (14.7)              | 5 (27.8)        | 29 (13.6)             | 0.103        |
| Valvulopathy, Yes (%)                | 4 (1.7)                | 1 (5.6)         | 3 (1.4)               | 0.195        |
| Family history of dialysis, Yes (%)  | 48 (20.8)              | 3 (16.7)        | 45 (21.1)             | 0.654        |
| History of smoking, Yes (%)          | 87 (37.7)              | 2 (11.1)        | 85 (39.9)             | 0.015*       |
| Consume alcohol, Yes (%)             | 5 (2.2)                | 0 (0.0)         | 5 (2.4)               | 0.509        |
| Tea intake, Yes (%)                  | 182 (79.1)             | 16 (88.9)       | 166 (78.3)            | 0.289        |
| Number of glasses of tea per week\(^6\) | 7 (2–14)              | 10.5 (7.0–19.3) | 7.0 (1–14)            | 0.140        |
| Coffee intake, Yes (%)               | 167 (72.6)             | 11 (61.1)       | 156 (73.6)            | 0.388        |
| Number of cups of coffee per week\(^6\) | 7 (1–14)              | 7 (0–7)         | 3 (0–14)              | 0.153        |

\(^6\)Median (interquartile range); *Mean ± SD; AF = atrial fibrillation
establish the diagnosis of subclinical AF. Most of our participants were within their fifth and sixth decades of life. This is a striking finding as it is the peak age for economic productivity and may therefore have a negative impact on the socioeconomic burden of ESRD in Jordan.

In the current study, age, history of smoking, history of ischaemic heart disease, and low interdialytic weight gain explained up to 25.4% of the total variability in the outcome. Age has been consistently reported in literature to be a strong predictor of AF [17, 18, 20, 24]. Aging is a normal physiological process which increases the individual’s risk of cardiovascular diseases such as hypertension, ischaemic heart diseases, and other comorbidities [24, 25]. These diseases are major risk factors for stroke. However, advanced age can directly cause AF even though the mechanism is still unclear [24]. However, existing theories suggest that advancing age leads to AF through atrial fibrosis, which is a major cause of atrial fibrillation [26]. Additionally, ischaemic heart failure is a well-established risk factor for AF [27]. A previous ischaemic heart disease will lead to cardiac remodeling, which predisposes the patient to aberrant intra-atrial conduction and consequently, AF [26]. Other cardiovascular disease risk factors such as heart failure and valvulopathy were

| Table 3 | Haemodialysis variables of participants |
|---------|-----------------------------------------|
| Variables | Total N = 231 (100.0%) | AF N = 18 (7.8%) | No AF N = 213 (92.2%) | p-value |
| Duration of dialysis (in hours) | 4 (3.0–4.0) | 3.5 (3.0–4.0) | 4.0 (3.0–4.0) | 0.260 |
| Number of sessions per week | 3 (3–3) | 3 (3–3) | 3 (3–3) | 0.230 |
| Dialysis access type | &nbsp;&nbsp; | &nbsp;&nbsp; | &nbsp;&nbsp; | 0.445 |
| Arteriovenous fistula | 177 (76.6) | 12 (66.7) | 161 (77.4) | &nbsp;&nbsp; |
| Arteriovenous graft | 3 (1.3) | 0 (0.0) | 3 (1.4) | &nbsp;&nbsp; |
| Central dialysis catheter | 51 (22.1) | 6 (33.3) | 44 (21.2) | &nbsp;&nbsp; |
| Pre-dialysis | &nbsp;&nbsp; | &nbsp;&nbsp; | &nbsp;&nbsp; | 0.436 |
| Average Systolic BP (in mmHg) | 133 ± 28.4 | 126.9 ± 34.5 | 133.6 ± 27.8 | &nbsp;&nbsp; |
| Average Diastolic BP (in mmHg) | 78.3 ± 13.5 | 71.3 ± 13.5 | 78.9 ± 13.4 | &nbsp;&nbsp; |
| Post-dialysis | &nbsp;&nbsp; | &nbsp;&nbsp; | &nbsp;&nbsp; | 0.034* |
| Average SBP (in mmHg) | 120.5 ± 28.6 | 121.0 ± 32.4 | 120.5 ± 28.3 | &nbsp;&nbsp; |
| Average DBP (in mmHg) | 73.3 ± 14.1 | 73.2 ± 14.5 | 73.3 ± 14.1 | &nbsp;&nbsp; |
| Average weight gain during dialysis (in kg) | 3.1 ± 1.0 | 2.6 ± 1.0 | 3.1 ± 1.0 | &nbsp;&nbsp; |

*Median (interquartile range); *Mean ± SD; AF = atrial fibrillation; BP = blood pressure; SD = standard deviation

| Table 4 | Drugs used by participants and relevant lab results |
|---------|-----------------------------------------|
| Variables | Total N = 231 (100.0%) | AF N = 18 (7.8%) | No AF N = 213 (92.2%) | p-value |
| Omeprazole, Yes (%) | 79 (34.2) | 4 (22.2) | 75 (35.2) | 0.392 |
| Lansoprazole, Yes (%) | 75 (32.5) | 6 (33.3) | 69 (32.4) | 0.935 |
| Beta-blocker, Yes (%) | 94 (40.7) | 5 (27.8) | 89 (41.8) | 0.362 |
| Calcium channel blocker, Yes (%) | 100 (43.3) | 4 (22.2) | 96 (45.1) | 0.102 |
| ACE inhibitor, Yes (%) | 10 (4.3) | 1 (5.6) | 9 (4.2) | 0.790 |
| Furosemide, Yes (%) | 53 (22.9) | 4 (22.2) | 49 (23.0) | 0.940 |
| Calcium carbonate, Yes (%) | 209 (90.5) | 16 (88.9) | 193 (90.6) | 0.811 |
| Vitamin D, Yes (%) | 26 (11.3) | 4 (22.2) | 22 (10.3) | 0.252 |
| Erythropoietin, Yes (%) | 77 (33.3) | 6 (33.3) | 71 (33.3) | 1.000 |
| Alpha 1 hydroxylase vit D, Yes (%) | 163 (70.6) | 15 (83.3) | 148 (69.5) | 0.333 |
| Labs | &nbsp;&nbsp; | &nbsp;&nbsp; | &nbsp;&nbsp; | &nbsp;&nbsp; |
| Low haemoglobin (anaemia), Yes (%) | 21 (9.1) | 1 (5.6) | 20 (9.4) | 0.891 |
| Serum Ca**+, Low (%) | 76 (32.9) | 6 (33.3) | 70 (32.9) | 0.922 |
| Serum K*, Low (%) | 7 (3.0) | 2 (11.1) | 5 (2.4) | 0.223 |
| Hypoalbuminemia, Yes (%) | 34 (14.7) | 2 (11.1) | 32 (15.0) | 0.885 |

AF = atrial fibrillation; ACE = Angiotensin converting enzyme
Table 5: Bivariate and multiple logistic regression analysis of factors associated with subclinical atrial fibrillation.

| Variables                                | OR (95% CI)       | p-value | Adjusted OR (95% CI) | p-value |
|------------------------------------------|-------------------|---------|----------------------|---------|
| Sociodemographic data                    |                   |         |                      |         |
| Age in years                             | 1.07 (1.03–1.12)  | 0.003*  | 1.05 (1.01–1.10)     | 0.031*  |
| Gender, Female                           | 1.64 (0.86–4.35)  | 0.323   |                      |         |
| Marital Status, Single                   | 0.30 (0.05–1.08)  | 0.111   |                      |         |
| Body mass index (BMI) (kg/m²)            | 1.00 (0.92–1.09)  | 0.912   |                      |         |
| Past Medical History                     |                   |         |                      |         |
| Hypertension, Yes (%)                    | 1.70 (0.53–7.51)  | 0.417   |                      |         |
| Diabetes mellitus, Yes (%)               | 2.04 (0.77–5.54)  | 0.151   |                      |         |
| Dyslipidaemia, Yes (%)                   | 1.19 (0.40–3.21)  | 0.738   |                      |         |
| Ischemic heart disease, Yes (%)          | 3.44 (1.12–9.68)  | 0.022*  | 3.74 (1.09–12.34)    | 0.033*  |
| Heart failure, Yes (%)                   | 2.44 (0.74–7.02)  | 0.113   |                      |         |
| Valvulopathy, Yes (%)                    | 4.12 (0.20–34.20) | 0.231   |                      |         |
| Family history of dialysis, Yes (%)      | 0.75 (0.17–2.39)  | 0.655   |                      |         |
| History of smoking, Yes (%)              | 0.19 (0.03–0.68)  | 0.029*  | 0.15 (0.02–0.60)     | 0.019*  |
| Consume alcohol, Yes (%)                 | 7.31e–07 (NA)     | 0.989   |                      |         |
| Tea intake, Yes (%)                      |                   | 0.300   |                      |         |
| Number of glasses of tea per week        | 1.01 (0.97–1.05)  | 0.522   |                      |         |
| Coffee intake, Yes (%)                   | 0.56 (0.21–1.60)  | 0.260   |                      |         |
| Number of cups of coffee per week        | 0.95 (0.88–1.01)  | 0.164   |                      |         |
| Dialysis                                 |                   |         |                      |         |
| Duration of dialysis (in hours)          | 0.57 (0.20–1.61)  | 0.292   |                      |         |
| Number of sessions per week              | 1.06 e07 (NA)     | 0.992   |                      |         |
| Dialysis access type                     |                   |         |                      |         |
| Arteriovenous fistula                    | Ref               |         |                      |         |
| Arteriovenous graft                      | 8.57 e–07 (NA)    | 0.992   |                      |         |
| Central dialysis catheter                | 1.83 (0.61–5.00)  | 0.253   |                      |         |
| Pre-dialysis                             |                   |         |                      |         |
| Average systolic BP (in mmHg)            | 0.99 (0.97–1.01)  | 0.340   |                      |         |
| Average diastolic BP (in mmHg)           | 0.95 (0.92–0.99)  | 0.024*  | 0.96 (0.92–1.00)     | 0.078   |
| Post dialysis                            |                   |         |                      |         |
| Average systolic BP (in mmHg)            | 1.00 (0.98–1.02)  | 0.943   |                      |         |
| Average diastolic BP (in mmHg)           | 1.00 (0.96–1.03)  | 0.966   |                      |         |
| Average weight gain during dialysis (in kg) | 0.55 (0.31–0.94) | 0.035*  | 0.50 (0.25–0.91)     | 0.031*  |
| Labs                                     |                   |         |                      |         |
| Low haemoglobin (Anaemia), Yes (%)       | 0.59 (0.03–3.13)  | 0.613   |                      |         |
| Serum calcium, Low (%)                   | 0.95 (0.32–2.56)  | 0.922   |                      |         |
| Serum potassium, Low (%)                 | 0.21 (0.04–1.59)  | 0.081   |                      |         |
| Hypoalbuminemia, Yes (%)                 | 1.48 (0.38–9.79)  | 0.621   |                      |         |

*Excluded during the backward elimination procedure; BP = Blood pressure; CI = confidence interval; OR = Odds ratio. Predictive power of final model: Nagelkerke pseudoR² = 0.254; C statistics = 82.2%; Goodness-of-fit: Hosmer-Lemeshow test (X² = 3.31, p = 0.913).

not significant in our study [17, 18, 20, 24]. This is most likely due to the small number of participants with these comorbidities, Table 2.
most part of literature, most studies conducted on ESRD patients on haemodialysis have failed to identify any associations [17, 18, 22, 25, 28]. Smoking was paradoxically protective against AF in our study. This finding was similar to those of Mariscalco and Engström who reported a protective effect of current smoking among participants who had undergone a coronary artery bypass and valvular surgical procedure [29]. However, a review by D’Alessandro et al. (2011) instead found smoking cessation to be preventive against AF [30]. A possible explanation for this association is that with chronic kidney disease being a chronic inflammatory state, ex-smokers whose cardiomyocytes have been exposed to higher adrenergic states can better tolerate the stress induced by chronic kidney disease and dialysis. However, this association is likely to be more complex and multifactorial, and there warrant further explorations.

Finally, in our study, lower interdialytic weight gain was associated with the occurrence of AF. Traditionally, higher interdialytic weight gain is linked to adverse morbidity and all-cause mortality and has been a growing
area of interest in dialysis medicine [31–33]. However, the association between interdialytic weight gain and AF is poorly established as this has been poorly studied in literature. Even though increasing interdialytic weight has been associated with cardiovascular morbidity such as ischaemic heart disease [34], little or nothing is known about its association with AF. This association is likely linked to the inverse correlation of interdialytic weight gain with age. That is, patients with higher interdialytic weight gain tend to be younger [31] and less likely to develop AF [17, 18, 20, 24]. Nevertheless, the association between interdialytic weight gain and AF remained true even after controlling for age. In one study, dialysis patients who were hypertensive due to hypervolemic state were found to have lower interdialytic weight gain which may partially explain the higher AF rate in these patients [35]. Additionally, a small group of patients with low interdialytic weight gain, especially those with no residual kidney function, were found to have protein-energy wasting, malnutrition, or intercurrent illness that may explain a higher AF rate [33].

Study limitations
Although we attained the minimum acceptable required sample size for this study, a larger sample size would have enabled us to detect smaller effects. Small sample sizes seem to be a major challenge for studies where data was collected prospectively using a cross-sectional design [18]. Most large-scale studies have been designed as either retrospective (using medical records) or prospective cohort. Also, despite the strict selection criteria including only patients without a prior diagnosis of AF, there is a possibility that we missed cases of paroxysmal AF. This study has several strengths. This is the first study on the subject in Jordan. Also, we established the diagnosis of AF based on recommended criteria. Furthermore, we used recommended and robust analytic techniques to build our regression model to make predictions with very good degree of accuracy.

Conclusions
The prevalence of subclinical atrial fibrillation among ESRD patients on maintenance dialysis was found to be high and this was mainly driven by advancing age, history of ischaemic heart disease, history of smoking, and lower interdialytic weight gain. ESRD is distinctive in Jordan because it affects mostly younger individuals at the prime of their economic productivity, thereby posing a significant socioeconomic burden. We suggest checking routinely for AF in patients on haemodialysis and if present to consider anticoagulant therapy as this may prevent serious complications. Finally, more large-scale studies are required on the national territory and the Middle East region, with the creation of national and regional registries for prospective observations.

Abbreviations
AF: Atrial fibrillation; CI: Confidence intervals; OR: Odds ratio; AOR: Adjusted odds ratio; CKD: Chronic kidney disease; ESRD: End stage renal disease; BP: Blood pressure; ECG: Electrocardiogram; SD: Standard deviation; IQR: Interquartile range; AIC: Akaike information criterion; ACE: Angiotensin converting enzyme

Acknowledgements
We thank Dr. Valirie Agbor for his great assistant in the data analysis and manuscript writing.

Authors’ contributions
IA designed and supervised the study. RA, NA and AO collected the data and entered to the Excel sheets. SI provided statistical advice and performed statistical analysis. IA, RA, NA and SI wrote the first draft of the manuscript. AS accustomed the study design and interpreted the ECGs. SJ recruited and supervised the patients and the study in Al-Essra and Islamic hospitals. AA contributed to literature review and manuscript editing. All co-authors contributed to the data acquisition and interpretation and provided critical feedback on drafts of the manuscript. All authors read and approved the final version of the manuscript.

Funding
Partial funding was received from the deanship of research of the University of Jordan.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the ethical review boards (IRB) of the Jordan University Hospital (Ref: 190/2018), Al-Essra, Al-Bashir, and the Islamic hospitals. All participants signed an informed written consent form after explaining the details of the research, its procedure, potential benefits and harm, and their questions were satisfactorily answered.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of medicine, the University of Jordan, PO Box 954180, Amman 11954, Jordan. 2 the University of Jordan, Amman, Jordan. 3 Al-Essra Hospital, Amman, Jordan. 4 King Hussein Medical Centre, Amman, Jordan.

Received: 19 June 2019 Accepted: 7 April 2020
Published online: 21 April 2020

References
1. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014;9:113–9.
2. Nouabi JI, Bigna JJ, Agbor VN, Mbanga C, Ndoadoumgue AL, Nkoeck JR, et al. Meta-Analysis of Atrial Fibrillation in Patients with Various Cardiomyopathies. Am J Cardiol. 2019;5002914919304679.
3. Agbor VN, Aminde LN, Tianyi F-L, Mbanga CM, Petnga S-JN, Ditah C, et al. Atrial fibrillation among adults with heart failure in sub-Saharan Africa — prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. BMJ Open. 2019;9:e022320.
4. Chugh SS, Blackshear JL, Shen W-K, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371–8.
5. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation. Circulation. 2014. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.
6. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11. https://doi.org/10.1371/journal.pone.0158765.

7. Genoveo RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet Lond Engl. 2013;382:339–52.

8. Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail Rev. 2015;20:259–72.

9. Liu M, Li X-C, Lu L, Cao Y, Sun R-R, Chen S, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18:2918–26.

10. United States Renal Data System. 2014 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2014. https://www.usrds.org/2014/view/. Accessed 29 Apr 2019.

11. Munger MA, Ateshkadi A, Cheung AK, Flaherty KJ, Stoddard GJ, Marshall EH. Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Am J Kidney Dis Off J Natl Kidney Found. 2000;36:130–9.

12. Francyzk B, Gluba-Bróżka A, Bartnicki P, Rysz J. The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. Int Urol Nephrol. 2017;49:1071–7.

13. Genovesi S, Fabbri A, Pienuzzi G, Galbiati E, Sironi E, Pogliani D, et al. Atrial fibrillation in end stage renal disease patients: influence of hemodialysis on P wave duration and atrial dimension. J Nephrol. 2015;28:615–21.

14. Buitien MS, de Bie MK, Rotmans JI, Gabreëls BA, van Dorp W, Wolterbeek R, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart. 2014;100:985–90.

15. Charytan DM, Foley R, McCullough PA, Rogers JD, Hsu C, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease in the elderly. J Geriatr Cardiol JGC. 2017;14:179–84.

16. Verde E, Pérez de Prado a, López-Gómez JM, Quiroga B, Goicoechea M, García-Prieto a, et al. asymptomatic Intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis. Clin J Am Soc Nephrol CJASN. 2016;11:721–34.

17. Königsbrügge O, Posch F, Antlanger M, Kovarik J, Klauser-Braun R, Kletzmayr et al. Risk Factor Management in Atrial Fibrillation. J - Risk Factor Manag Atr Fibrillation: Nguyen BO; 2018. https://www.aerjournal.com/articles/risk-factor-management-atrial-fibrillation.

18. Watanabe I. Smoking and risk of atrial fibrillation. J Cardiol. 2018;71:111–2.

19. Mariscalco G, Engström KG. Are current smokers paradoxically protected against atrial fibrillation after cardiac surgery? Nicotine Tob Res Off J Soc Res Nicotine Tob. 2009;11:58–63.

20. D’Alessandro A, Boeckelmann I, Hammwhöner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol. 2012;19:297–305.

21. Jeljasz A, Charytan DM, Caramori G, Correa-Rotter R, Hsu C, Ordonez JD, Marcus GM, Go AS. Independent risk factors for atrial fibrillation in a population-based cohort. Framingham Heart Study JAMA. 1994;271:840–4.